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ABSTRACT 
 
Purpose of review: Age has remained one of the most important determinants of risk for 
the development of certain brain tumors, of benefit from and tolerance of brain tumor 
treatment, and overall outcome. Regarding these three aspects, there are major 
differences across the spectrum of primary brain tumors depending on specific 
histology. Here we review recent advances in understanding the biological basis of the 
prognostic marker “age” in Neuro-Oncology.  
Recent findings: Contemporary population-based studies confirm the strong prognostic 
impact of age in many brain tumors. Elderly patients continue to be treated less 
aggressively than younger patients with the same tumors. However, biological factors 
may contribute to the negative prognostic impact of age. For instance, among gliomas, 
mutations of the isocitrate dehydrogenase (IDH) genes, which are prognostically 
favourable, are much more common in younger patients. Moreover, complete 
responses defined by neuroimaging were much less durable in elderly as opposed to 
younger patients with primary central nervous system lymphoma in the G-PCNSL-SG-1 
trial. 
Summary: A combination of age-adapted patterns of care and treatment-independent, 
tumor-intrinsic factors contributes to the poorer outcome of elderly patients with brain 
tumors. These factors need to be better distinguished and understood in order to 
improve outcome in elderly brain tumor patients. 
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Introduction 
 
The population of Western societies undergoes a dramatic change in that the proportion 
of the elderly, overall less fit population increases steadily. This will result in altered 
incidences and prevalences of age-associated diseases and may necessitate specific 
therapeutic approaches to diseases, notably cancer, when these are diagnosed in the 
elderly 1. Yet, for many diseases, including many types of cancer, the best treatment, 
its tolerability and efficacy, are vaguely defined in elderly patients because clinical trials 
may have had an upper age limit or because these patients were considered too frail to 
be included in a clinical trial. A retrospective analysis of 59,300 patients from 495 
cooperative group trials sponsored by the National Cancer Institute, performed from 
1997 through 2000, showed that 32% of the participants in phase II and III clinical trials 
were elderly defined as aged 65 or more. In contrast, the relative contribution of this 
patient population to cancer diagnoses in general in the United States was 61%, 
illustrating that elderly patients are strongly underrepresented in clinical trials. This 
pattern of preferential enrolment of younger patients was not specific to brain tumors 
2. The diagnosis of brain tumors in elderly patients who often exhibit significant 
comorbidity (see below) raises distinct questions that differ from those relevant for 
younger patients where this diagnosis is usually the major limitation of life expectancy. 
In the elderly, the treatment of brain tumors is less often curative and will focus more 
strongly on preservation of quality of life respectively maintaining functional 
independence. Moreover, as our health care systems and our treatment options evolve, 
the definition of “elderly” has changed and will continue to do so. The current cut-off of 
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younger versus elderly is likely to be in the range of 70, but this may vary in a disease-
specific manner, for instance, in the field of brain tumors, the likely cut-off would be 60 
to 65 in primary central nervous system lymphoma where the question focuses on the 
decision between high-dose versus conventional dose chemotherapy or the benefit from 
intrathecal treatment , but more likely to be 65-70 for malignant gliomas where the 
choice is between single modality versus multimodality management approaches, that 
is, radiotherapy or chemotherapy alone versus their combination. Importantly, for the 
future, it is mandatory to better distinguish the concepts of elderly cancer patients from 
cancer patients with frailty, a poorly defined constellation of being less fit and at higher 
risk of intolerance of cancer treatment that is strongly age-related. 
 
 
Brain tumor epidemiology by age 
 
The most reliable and extensive data to estimate the risk of brain tumor development by 
age are provided by the Central Brain Tumor Registry of the United States 
(www.cbtrus.org). The table shows median ages at diagnosis and age-specific survival 
by histology. Embryonal tumors with a median age at diagnosis of 9 years, and pilocytic 
astrocytomas 13 years, are predominantly tumors of childhood whereas glioblastomas 
and lymphomas as well as meningiomas are typical brain tumors associated with 
advanced age. Moreover, looking at outcome by age, it has long been recognized how 
strong the impact of age at diagnosis is on outcome in most types of glioma as well as 
brain lymphoma. In contrast, this seems not be true for ependymomas, neuronal/glial 
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tumors and embryonal tumors. Many of the differences by age are therefore more likely 
caused by age-specific changes in the biology of some tumors rather than age-specific 
treatment approaches alone. 
 
 
Comorbidity and complications of treatment 
 
It is often assumed that elderly patients tolerate brain tumor treatment less well and that 
the natural course of brain tumors in the elderly is more aggressive. However, these 
assumptions are only partially true and disease-specific considerations are required 
(see below). It is important to understand that it is probably not age per se, but rather 
the increased prevalence of significant comorbidities that increases the risk of side 
effects and decreases the tolerability of most treatments for cancer, including major 
surgery, radiotherapy and chemotherapy. Moreover, polypharmacy associated with age 
may be more predictive of side effects from chemotherapy than age alone. 
Specifically the brain of the elderly is considered more sensitive to the possible 
detrimental effects of therapeutic irradiation. This has been demonstrated most clearly 
in patients with primary central nervous system lymphoma who were treated with 
combined systemic and intrathecal chemotherapy plus whole brain radiotherapy. In this 
patient population, age was a powerful predictor of severe neurotoxicity 3. However, 
the latter is less clear than generally assumed when looking at focal irradiation. An 
analysis of acute and late grade 3 neurological toxicities among 2761 patients from 14 
RTOG trials accrued from 1983 to 2003 showed an age association only on univariate 
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analysis, but not on multivariate analysis 4. Moreover, the risk of cerebral radiation 
necrosis in glioma patients treated with focal radiotherapy was not age-related 5. The 
recently published German Primary Central Nervous System Lymphoma trial (G-
PCNSL-SG-1 trial) on the role of whole brain radiotherapy in primary central nervous 
system lymphoma is particularly useful to study the link between age and tolerability of 
treatment. Although the dose of high-dose methotrexate was adapted to the glomerular 
filtration rate, hematogical WHO grade III/IV toxicity was twice as common in patients 
aged 60 more than in younger patients whereas no relevant difference was observed for 
non-hematogical toxicity 6. 
Finally, there is a significant risk of cognitive impairment with increasing age and the 
ability to consent to treatment is more often questionable than in younger patients. This 
limits the suitability of many, particularly less fit brain tumor patients for inclusion in 
clinical trials as well as the use of experimental treatment strategies outside clinical 
trials. Moreover, not only therapeutic irradiation, but also chemotherapy has increasingly 
been reported to promote cognitive decline 7. While the concept of the “chemobrain” is 
currently of concern predominantly in long-term survivors of cancer who are less 
frequent in the elderly, it can nevertheless be predicted that such chemotherapy-
associated cognitive changes may affect elderly patients more severely than younger 
adult patients, simply because of less neurological comorbidity, e.g., dementing and 
cerebrovascular diseases. 
 
 
Tumor-specific considerations 
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Gliomas 
Among the astrocytic gliomas, there is a clear age-dependent differential distribution of 
histological subtypes corresponding to grade of malignancy, molecular features such as 
epidermal growth factor receptor (EGFR) amplification and p53 mutation, and outcome 
(Table). WHO grade I pilocytic astrocytomas are typical tumors of children and 
adolescence and are probably biologically unrelated to the astrocytic gliomas of higher 
grades (II-IV). They are the most common brain tumor in children aged 5-14. 
For astrocytic and oligodendroglial tumors of grades II to IV, a strong negative impact of 
age probably irrespective of treatment intensity is not disputed. Age has been identified 
as a prognostic factor both in the Radiation Therapy Oncology Group (RTOG) 
Recursive Partitioning Analysis (RPA) score for malignant gliomas 8,9 as well as the 
prognostic score for patients with low grade gliomas derived from analyses of the 
European Organization for Research and Treatment of Cancer (EORTC) trials 22844 
and 22845 10. A more contemporary series of low grade gliomas from France showed 
that elderly patients aged ≥ 60 more often presented with a clinical deficit, a lower 
Karnofsky performance score, a larger tumor, and a lower rate of tumor resection. 
Exclusive chemotherapy was more often used as the first-line treatment in elderly 
glioma patients . Of patients dying from progressive tumor, 55% of the elderly had not 
received radiotherapy compared to 11% in the younger patients 11. 
Among malignant gliomas, the same treatment confers less benefit to elderly patients 
as compared with younger patients, both in anaplastic glioma 12 and in glioblastoma 
13.  
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The elucidation of the age-dependent frequency and prognostic role of mutations of the 
isocitrate dehydrogenase (IDH) genes in gliomas has provided the first major molecular 
marker that may account for the negative prognostic impact of age. Within one 
histological entity, IDH mutations are prognostically favourable, and they are virtually 
absent in malignant gliomas in patients aged 60 or more: in fact, a retrospective 
analysis of patients from the NOA-04 anaplastic glioma trial and the German Glioma 
Network provided evidence that the IDH1 status is more prognostic for overall survival 
than standard histological criteria that differentiate high-grade astrocytomas (Hartmann 
et al. 2010). Among 382 patients with grade III/IV gliomas, IDH1 mutation status was 
the most prominent single prognostic factor, followed by age, diagnosis and O6-
methylguanylmethyltransferase (MGMT) status. The sequence from more favorable to 
poorer outcome was (i) anaplastic astrocytoma with IDH1 mutation, (ii) glioblastoma 
with IDH1 mutation, (iii) anaplastic astrocytoma without IDH1 mutation and (iv) 
glioblastoma without IDH1 mutation 14. Recent analyses in elderly glioblastoma 
patients have revealed an increased prevalence of MGMT promoter hypermethylation 
(50-60%) compared with the general population of glioblastoma patients 15,16. 
Nonetheless, prognosis in this patient group is considerably worse and the prognostic 
value of MGMT less clearly defined. It remains to be determined whether these 
differences are tumor-specific or reflect an age-related increase in methylation 17.  
 
 
Specifically in the controversial field of glioblastoma in the elderly, a series of clinical 
trials have been designed to clarify the best treatment: a French trial demonstrated the 
9 
 
superiority of radiotherapy over best supportive care 18 and a Canadian trial indicated 
that hypofractionated radiotherapy at 2.66 Gy in 15 fractions to 40 Gy is as effective as 
convential fractionation at 2 Gy in 30 fractions to 60 Gy 19. More recently, two larger 
phase III trials showed that there is probably little difference between radiotherapy alone 
and temozolomide alone in terms of overall survival 20,21. Also, in elderly (≥ 70 years) 
and less independent (KPS < 70) patients with glioblastoma, temozolomide seems to be 
a well-tolerated and effective option 22. Importantly, there are concerns that combined 
modality treatment may be both less active and less well tolerated in the elderly 23. A 
National Cancer Institute of Canada / EORTC trial comparing radiotherapy alone and 
radiotherapy plus temozolomide is ongoing. 
Finally, the introduction of anti-angiogenic agents into the management of malignant 
gliomas has probably for the first time led to the identification of a preferential benefit 
from a given treatment in the elderly: in a phase II trial of the vascular endothelial 
growth factor (VEGF) antibody bevacizumab alone, the median progression-free 
survival for patients with a median age of 53 years or older was 30 weeks versus a 
median progression-free survival of 11 weeks for younger patients 24, and patients of 
older age (>55 years) and poor performance status (Karnofsky performance score <80) 
had significantly better progression-free survival when treated with bevacizumab, and 
bevacizumab-treated older patients had significantly increased overall survival, in a 
single institution report 25. These observations indicate that glioblastomas in the 
elderly may be more VEGF-dependent than glioblastomas in younger patients. 
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Primary central nervous system lymphoma 
 
As outlined above, the dramatically increased risk of severe neurotoxicity with higher 
age has been most clearly delineated in patients with primary central nervous system 
lymphoma. However, this patient population has also revealed that there are clear age-
dependent differences in response rate, duration of response, and benefit from salvage 
treatment. In the G-PCNSL-SG-1, median overall survival was 14.2 months for patients 
aged 60 or more versus 38.4 months for patients aged 59 or less 6. As in 
glioblastoma, there is now general agreement that separate clinical trials for younger 
and elderly patients with cerebral lymphoma are required, with cure as the goal in 
younger patients and maintaining remission and (neurocognitive) function as the goal in 
the elderly. 
 
 
Brain and leptomeningeal metastases 
 
Brain metastases are the most common brain tumors in adults. For elderly patients with 
systemic cancer who develop brain or leptomeningeal metastases, most of the above-
mentioned considerations regarding maintenance of quality of life and tolerance of 
treatment may be even more relevant than for patients with primary brain tumors. 
Specifically for patients with leptomeningeal metastases, aggressive treatment is 
typically administered preferentially to younger patients 26. However, given the 
increasing repertoire for pharmacological treatments for systemic cancer, the likelihood 
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of achieving control of systemic disease should guide treatment decisions more than 
age alone, and clinical trials on central nervous system involvement in systemic cancer 
should probably consider the histology of the primary tumors more than in the past. 
The first widely used prognostic score had already incorporated an age cut-off of 70 
27. More recent revisions of prognostic score concepts stress the relevance of age 
and even introduced three age categories of 49 or less, 50-59, and 60 or more 28,29. 
Accordingly, future studies on the optimization of brain metastasis treatment should 
consider age at least as a stratification factor or even as a stratum to design age-
dependent trials such as in glioblastoma or primary central nervous system lymphoma. 
 
 
Conclusions 
 
Age remains to be one of the most important prognostic factors in the clinical course of 
brain tumors. Commonly age is a negative prognostic factor as exemplified by a 
plethora of data on patients with gliomas, primary central nervous system lymphomas 
and brain metastases. Specifically in gliomas, the poorer outcome in the elderly may not 
result only from less aggressive treatment, but also from a distinct pattern of molecular 
changes rendering tumors in the elderly less responsive to treatment. Moreover, there is 
a relative paucity of data on treatment in the elderly from clinical trials. The 
underrepresentation of elderly patients in clinical trial populations has probably multiple 
reasons: previously, many trials had upper age limits because an increased rate of side 
effects was feared; pharmaceutical companies may have been particularly concerned 
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about severe side effects in the elderly, affecting the safety profile and thus reputation of 
new drugs in general; elderly patients are very likely to exhibit more comorbidity 
rendering compliance with inclusion and exclusion criteria less likely. 
 
 
Key points 
 Age strongly determines the risk of development for specific types of brain 
tumors. 
 Age is a major therapy-independent prognostic factor for brain tumor patients. 
 Age is associated with less aggressive treatment of brain tumors. 
 Age is associated with specific molecular features of glial brain tumors, e.g., 
presence of EGFR amplification and absence of IDH and p53 mutations. 
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Table. Brain tumor epidemiology: median age at diagnosis and survival by age (www.cbtrus.org) (nd no data). 
 
 
Histology 
(median age 
at diagnosis) 
Age group Cases (n) 1-year 
survival rate 
2-year 
survival rate 
5-year 
survival rate 
10-year 
survival rate 
Pilocytic 
astrocytoma 
(13) 
0-14 1,366 98.7% 98.6% 97.3% 96.1% 
 0-19 1,644 98.4% 98.4% 96.8% 95.6% 
 20-44 491 96.8% 95.2% 91.0% 87.9% 
 45-54 88 94.3% 88.0% 82.4% 72.4% 
 55-64 40 95.4% 84.0% 81.0% nd 
 65-74 22 nd nd nd nd 
 75+ Nd nd nd nd nd 
Diffuse 
astrocytoma 
(47) 
0-14 89 93.1% 84.3% 84.3% 82.1% 
 0-19 110 94.4% 85.1% 85.1% 79.6% 
 20-44 243 91.6% 81.4% 58.5% 40.7% 
 45-54 81 71.6% 52.8% 39.5% Nd 
 55-64 96 55.1% 29.5% nd Nd 
 65-74 58 nd nd nd Nd 
 75+ 38 nd nd nd Nd 
Anaplastic 
astrocytoma 
(52) 
0-14 150 59.7% 43.5% 32.0% 27.7% 
 0-19 200 63.7% 44.5% 33.6% 30.1% 
 20-44 933 87.3% 72.7% 48.5% 36.5% 
 45-54 532 70.1% 48.2% 28.6% 18.6% 
 55-64 485 46.9% 21.6% 8.2% 5.7% 
 65-74 411 30.7% 11.0% 3.3% Nd 
 75+ 285 12.9% 5.2% nd nd 
Glioblastoma 
(64) 
0-14 155 46.6% 26.0% 20.9% 13.3% 
 0-19 239 54.5% 29.5% 18.6% 12.7% 
 20-44 2,052 66.1% 34.3% 16.1% 9.7% 
 45-54 3,561 51.8% 18.7% 5.6% 3.1% 
 55-64 4,931 39.8% 12.4% 3.3% 0.8% 
 65-74 4,831 22.3% 5.5% 1.4% 0.8% 
 75+ 4,183 9.7% 2.4% 0.7% c 
Oligodendrogli
oma (41) 
0-14 114 97.3% 96.4% 95.3% 90.6% 
 0-19 191 97.4% 95.1% 92.5% 88.6% 
 20-44 1,304 98.0% 95.7% 84.7% 67.2% 
 45-54 526 94.3% 88.9% 76.8% 55.8% 
 55-64 255 87.2% 78.0% 65.0% 46.9% 
 65-74 109 78.4% 68.6% 51.5% 35.1% 
 75+ 68 57.9% 42.6% 30.4% Nd 
Anaplastic 
oligodendroglio
ma (49) 
0-14 nd nd nd nd nd 
 0-19 27 88.5% nd nd nd 
 20-44 395 93.2% 81.8% 65.9% 46.8% 
 45-54 238 83.3% 70.0% 52.9% 40.1% 
 55-64 170 72.3% 55.4% 32.5% 16.7% 
 65-74 100 50.3% 35.1% nd nd 
 75+ 40 nd nd nd nd 
Ependymoma 
and anaplastic 
ependymoma 
(40) 
0-14 433 93.4% 85.6% 69.9% 60.5% 
 0-19 520 94.2% 86.9% 72.8% 63.3% 
 20-44 564 95.9% 94.4% 90.9% 87.1% 
 45-54 304 94.3% 90.4% 84.9% 81.8% 
 55-64 209 92.5% 88.3% 84.4% 83.6% 
 65-74 100 88.6% 76.2% 72.0% 58.6% 
 75+ 51 83.2% 74.1% 63.4% 32.4% 
Malignant 
neuronal/glial, 
neuronal and 
mixed  
(26) 
0-14 92 86.3% 76.0% 69.6% 69.6% 
 0-19 112 86.9% 75.5% 67.4% 67.4% 
 20-44 134 93.3% 87.7% 77.2% 66.0% 
 45-54 114 91.4% 88.7% 75.8% 58.9% 
 55-64 87 89.9% 72.1% 61.1% 54.7% 
 65-74 43 72.4% 62.6% 60.5% nd 
 75+ 36 77.3% 65.8% 55.5% nd 
Embryonal/pri
mitive/medullo
blastoma  
(9) 
0-14 1,232 80.7% 69.8% 61.8% 56.9% 
 0-19 1,358 81.6% 70.4% 61.7% 57.0% 
 20-44 407 87.0% 79.7% 66.0% 55.1% 
 45-54 53 80.9% 64.5% 55.7% 34.5% 
 55-64 26 69.2% nd nd nd 
 65-74 nd nd nd nd nd 
 75+ nd nd nd nd nd 
Lymphoma 
(63) 
0-14 37 86.3% 82.8% 77.3% 77.3% 
 0-19 59 82.7% 78.6% 75.6% 65.1% 
 20-44 887 37.2% 31.4% 25.8% 19.8% 
 45-54 574 57.9% 48.9% 39.3% 29.0% 
 55-64 615 61.2% 50.6% 37.3% 27.1% 
 65-74 689 48.2% 37.7% 21.1% 9.3% 
 75+ 597 33.8% 23.1% 12.1% 9.7% 
Total: all brain 
and CNS 
0-14 5,596 85.6% 77.9% 71.9% 67.8% 
 0-19 6,839 86.6% 78.8% 72.5% 68.6% 
 20-44 10,472 82.6% 70.8% 56.6% 45.0% 
 45-54 7,486 65.2% 43.7% 31.2% 23.4% 
 55-64 8,125 49.6% 27.4% 17.4% 12.6% 
 65-74 7,555 31.2% 16.3% 9.8% 6.9% 
 75+ 7,215 16.5% 8.8% 5.4% 4.0% 
 
